CALR — gene · CancerIndex

Curated evidence

Clinical evidence (8)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–8 of 8 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CALR EXON 9 FRAMESHIFT7
(prognostic)	Primary MyelofibrosisALIAS	Prognostic	A	Supports Better Outcome	4	accepted	EID1387 Study of 428 patients with primary Myelofibrosis found that those patients harboring CALR exon 9 mutations displayed significantly longer survival than those with JAK2 mutations (HR: 2.5, median survi… (full text at CIViC) PMID 25037629 · Tefferi et al., 2014 · Open in CIViC	civic
〃	Primary MyelofibrosisALIAS	Prognostic	B	Supports Better Outcome	4	accepted	EID1649 In patients with primary myelofibrosis CALR mutations were associated with improved median survival. For 277 patients, CALR mutated, ASXL1 wildtype patients (median survival, 10.4 years, N=46); CALR w… (full text at CIViC)

Cohorts

Alteration frequency by cohort (37)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved37 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Myeloproliferative Neoplasms (CIMR, NEJM 2013) mpn_cimr_2013	Myeloproliferative Neoplasm	Ssm	25	151

Literature

Linked publications (4)

25 per page, newest first.

pubmedPublishedShowing 1–4 of 4 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
· Blood · 2016 · PMID 27069254 · validated civic_curation pubmed
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
· Blood · 2014 · PMID 25037629 · validated civic_curation pubmed
Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.
· Blood · 2015 · PMID 26486786 · validated civic_curation pubmed
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.
· Leukemia · 2014 · PMID 24496303 · validated